As spring legislative sessions wind down across the country, some state lawmakers are racing to pass a diverse wave of psychedelic-related bills.
From Colorado’s upcoming data collection system to New Mexico’s landmark psilocybin access law and Texas’ flurry of psychedelic-related efforts, here’s a state-by-state look at the major developments… and where the clock may run out.
***
In this Article:
- Colorado: New Data Collection Rules for State Psychedelics Program
- New Mexico: Medical Psilocybin Act Signed Into Law Creating Nation’s First Legislature-Driven Psilocybin Access Program
- Texas: Ibogaine Study Bill Passes House, Advocates Rush to Get it to Governor’s Desk in Coming Weeks
- West Virginia: Ibogaine Drug Development Fund Bill Laid Over
- Texas: Desk-Based Study Into Psychedelics for PTSD, Depression Passes House
- Oregon: Oregon Psilocybin Services Program Improvement Bill Passes House
- California: Amendments Shift Responsibility for Psilocybin Pilot Program to University of California
- Iowa: Effort to Establish State-Legal System for Psilocybin for PTSD Passes House, But Legislative Session Over
- Nevada: Senate Mulls Joint Resolution Calling on Federal Government to Support Psychedelic Research
- Arizona: Oregon-Style Psilocybin Services Bill Gutted, Replaced with Compass Pathways’ Crystalline Polymorph Psilocybin Rescheduling Trigger Law Bill
- Iowa: Compass Rescheduling Trigger Law Bill Passes House and Senate Unanimously
- Hawaii: Senate Rejects House Amendments to Pilot Program Bill, which Fails to Pass During Legislative Session
- Missouri: Veteran-Focused Psilocybin Pilot Program Bill Dropped from Calendar
- Georgia: Compass Crystalline Polymorph Rescheduling Trigger Law Bill and Regulation of Psychedelic-Assisted Treatment Bill Both Stall
- Oregon: Ibogaine for PTSD Access Program Bill Stripped Back to a Study, Progress Stalls
- Florida: Farm Bill Passes, Criminalises Psilocybin Mushroom Spores
- Missouri: Senator Unsuccessfully Tries to Shoehorn Psilocybin Into Hyperbaric Oxygen Bill
***
Colorado SB25-297: New Data Collection Rules for State Psychedelics Program
Introduced by Democrats Matt Ball and Lisa Feret, this bill directs Colorado’s Department of Public Health and Environment (CDPHE), in coordination with the Departments of Revenue (DOR) and Regulatory Agencies (DORA), to collect data related to the use of natural medicine through the state’s program. (At present, the only ‘natural medicine’ that will be available through the system, which is set to launch imminently, is psilocybin.)
Specifically, CDPHE must collect de-identified data from healing centres and licensed facilitators starting July 2026, including client demographics, health outcomes from the dosing sessions, impacts on behavioural health, law enforcement and hospital interactions, and more. For full details of the requirements, refer to the text of the bill.
The bill passed the Senate on the last day of April and has since passed the House.
New Mexico SB 219: Medical Psilocybin Act Signed Into Law Creating Nation’s First Legislature-Driven Psilocybin Access Program
In early April, New Mexico Governor Michelle Lujan Grisham (D) signed SB 219, the Medical Psilocybin Act, which will establish the third state-legal psilocybin access system in the US.
We covered this in detail:
Texas SB 2308/HB 3717: Ibogaine Study Bill Passes House, Advocates Rush to Get it to Governor’s Desk in Coming Weeks
On the last day of April, the Texas Senate fast-tracked the passage of this bill by suspending the rule that requires a bill be read on three separate days. Instead, the SB 2308 was read three times, back-to-back, that day and received three overwhelming ‘yes’ votes and final passage in less than four minutes! In presenting the bill to the Senate, its sponsor Tan Parker (R) told lawmakers that the program “relies only on private funds.”
The bill, which would create a fund to support FDA-approvable ibogaine drug development, has now been referred to the House. But with Texas’ legislative session coming to a close on the second of June, it’s a race to get the Senate version of the bill voted on.
To continue reading, please log in or join Pα+…
Join Pα+ Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Already a member? Log In
✓ Regular Bulletins covering key topics and trends in the psychedelics space
✓ Regular articles and deep dives across psychedelic research, policy and business
✓ Interviews with insiders
✓ Monthly interactive database and commentary on psychedelic patents
✓ Quick-take analysis of major developments
✓ A Library of primers and explainers
✓ Access to our full back catalogue
